Navigation Links
H&V Introduces HVision Technology Platform to Accelerate Development of Breakthrough Products
Date:11/13/2007

EAST WALPOLE, Mass., Nov. 13 /PRNewswire/ -- Hollingsworth & Vose Company (H&V), a leading global provider of nonwovens and technical papers, today introduced its HVision(TM) technology platform, a collaborative process designed to enhance the development and commercialization of breakthrough products.

"HVision will provide H&V with an enhanced R&D process focused on creating a new generation of products that exceed present performance benchmarks in the industry," said Val Hollingsworth, H&V's President and Chief Executive Officer.

Hollingsworth said the HVision technology platform consists of a development process focused on three key principles:

-- Benchmarking the industry's best performance on the metrics most

important to the customer

-- Developing technologies that exceed those benchmarks to achieve

breakthrough performance levels

-- Focusing on creating core materials technologies that deliver unequaled

performance across multiple products and markets

"This R&D platform will provide customers with innovative products that offer new standards of excellence for the performance characteristics that matter most," said Hollingsworth. "In addition, it will accelerate product development cycles and improve quality."

New HVision Products to Debut in Q4

H&V also announced that the first new products developed with the HVision technology platform will be commercially available in the fourth quarter of 2007. They are:

-- The PerForm(TM) next-generation HEPA/ULPA filter media for clean room

applications. PerForm sets new generation standards for performance

across the board, including:

-- Setting the standard for performance and processability

-- Increasing filter performance with lower pressure drop

-- Maximizing filter production line productivity

-- Ensuring high quality pleats through superior uniformity

-- The new NanoWave(TM) patented, extended surface, high loft all-

synthetic media for the ASHRAE bag filter market with three times the

dirt-holding capacity of conventional media. NanoWave features:

-- Half the resistance at a given efficiency versus standard synthetic

media in an uncharged state

-- Excellent dust holding capacity

-- High stiffness to maintain shape during filter life

-- Unique benefits for a wide range of air filtration applications

"This introduction represents the first of many exciting new capabilities to come from our HVision process," said Hollingsworth. "We anticipate this technology platform will produce additional next-generation filtration and industrial specialty products in 2008."

About H&V

Hollingsworth & Vose Company, established in 1843, is a global leader in the supply of technically advanced filtration media, battery separator materials and industrial nonwovens. The company operates manufacturing sites and research centers in the Americas, Europe and Asia. Visit Hollingsworth & Vose Company on the Net at http://www.hollingsworth-vose.com.


'/>"/>
SOURCE Hollingsworth & Vose Company
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
2. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
3. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
4. Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures
5. Advanced Instruments Introduces Worlds Fastest High Throughput Freezing Point Osmometer
6. Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology
7. Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features
8. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. WHO Introduces the Helminth Drug Initiative With Special Supplement in the Expert Opinion on Drug Discovery
11. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 18, 2017   Boston Biomedical , an industry ... target cancer stemness pathways, will feature data from two ... the 2017 ASCO Gastrointestinal Cancers Symposium, held from January ... Napabucasin is an orally-administered investigational agent designed ... Cancer stem cells (CSCs) possess the property of ...
(Date:1/18/2017)... ... 2017 , ... Whitehouse Labs has furthered its efforts towards ... (AMRI), the scientific staff dedicated to Extractables / Leachables & Impurities has more ... 2017. Extractable & Leachable evaluations have become increasingly more vital to successful product ...
(Date:1/18/2017)... ... January 18, 2017 , ... BidMed, LLC, ... research and genetic testing lab equipment from two different leading institutes. This highly specialized ... regions of the United States. This 1-day online auction will take place on ...
(Date:1/18/2017)... Jan. 18, 2017  Caris Life Sciences, a ... Foundation, the largest private funder of pancreatic cancer ... evaluating the impact of immunotherapy in the treatment ... enrollment services to identify potential trial candidates based ... treating physicians and study investigators. The Lustgarten Foundation ...
Breaking Biology Technology:
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/3/2017)... 2017 Onitor, provider of digital health technology ... an innovative biometric data-driven program designed to aid weight ... the 2017 Consumer Electronics Show (CES) in ... U.S., the World Health Organization (WHO), have identified lifestyle ... who are overweight or obese. WHO also states that ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL anunció ... acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar a ... con múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el ... de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos ...
Breaking Biology News(10 mins):